Precision medicine is tailored to the individual patient instead of a one‐drug‐fits‐all model. By finding exquisitely sensitive cancer subtypes and developing highly selective therapeutics, the therapeutic efficacy of a drug or drug combination can be enlarged, leading to a much greater chance of success in clinical trials.
NTRC’s mission is to develop targeted small molecules for cancer therapy. Our science platforms deliver proof of concept via biomarker identification using advanced bioinformatics and drug-interaction studies. We aim to find the informed route to the clinic for our highly selective inhibitors with prolonged pharmacological effects. Clinical development of our inhibitors is driven by mechanistic hypotheses.